Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.

Abstract

In this review, the clinical pharmacology of high-dose doxorubicin is examined, and the pharmacokinetics of infusional doxorubicin at standard and high dose are compared. The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support.

• Authors: T W Synold, J H Doroshow
• Journal: The Journal of infusional chemotherapy (J Infus Chemother) Vol. 6 Issue 2 Pg. 69-73 ( 1996) ISSN: 1060-0051 [Print] UNITED STATES
• PMID: 8809652 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Antibiotics, Antineoplastic
• Doxorubicin

Topics

• Antibiotics, Antineoplastic (administration & dosage, pharmacokinetics)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Doxorubicin (administration & dosage, pharmacokinetics)
• Drug Administration Schedule
• Humans
• Infusions, Intravenous
• Neoplasms (drug therapy)